This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Aptevo Therapeutics Inc.
Drug Names(s): Rho (D) Immune Globulin Intravenous, WinRho, WinRho SD, WinRho 1500 LQ
Description: WinRho SDF is a sterile freeze-dried gamma globulin (IgG) fraction of human plasma containing antibodies to Rho (D) antigens. In conditions when self-antibodies bind to platelets, such as immune thrombocytopenic purpura (ITP), the antibody-coated platelets are marked for destruction by phagocytic cells. It is believed that WinRho SDF's primary mechanism of action is Fc-receptor blockade. WinRho SDF contains a high percentage of antibodies that bind the D marker on red blood cells resulting in a complex that blocks Fc receptors thus sparing platelets.
Deal Structure: In March 2005, Baxter Healthcare and Cangene announced that, effective immediately, Baxter has assumed exclusive rights to market and distribute Cangene's WinRho SDF [Rho(D) Immune Globulin Intravenous (Human)] in the United States.
In April 2010, Cangene reports that it has signed a new agreement with Baxter Healthcare under which Cangene assumes the commercialization rights to WinRho SDF for the U.S. market. Cangene and Baxter have mutually agreed to terminate an existing U.S. distribution agreement.
Cangene and Emergent
In December 2013, Cangene announced the signing of a definitive agreement under which Emergent will acquire Cangene in an all-cash transaction valued at US$222 million (approximately C$236 million). Under the terms of the agreement, Cangene shareholders will receive US$3.24 per share (C$3.44 per share) in cash. The purchase price represents a premium of approximately 27% to Cangene's closing stock price of $2.70 on December 10, 2013 and 45% to...See full deal structure in Biomedtracker
WinRho SDF News
Pink Sheet Licensing In Brief
Additional information available to subscribers only: